Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial

D. Hong; A. Shergill; L. Bazhenova; B. C. Cho; R. Heist; V. Moreno; G. S. Falchook; M. Nagasaka; P. Cassier; B. Besse; D. W. Kim; S. Yoon; X. Le; T. Zhao; S. Atwal; E. Park; J. Lee

doi:10.1016/S0959-8049(22)00992-3

Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial

D. Hong, A. Shergill, L. Bazhenova, B. C. Cho, R. Heist, V. Moreno, G. S. Falchook, M. Nagasaka, P. Cassier, B. Besse, D. W. Kim, S. Yoon, X. Le, T. Zhao, S. Atwal, E. Park, J. Lee

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	S72
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)00992-3
State	Published - Oct 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0959-8049(22)00992-3

Cite this

Hong, D., Shergill, A., Bazhenova, L., Cho, B. C., Heist, R., Moreno, V., Falchook, G. S., Nagasaka, M., Cassier, P., Besse, B., Kim, D. W., Yoon, S., Le, X., Zhao, T., Atwal, S., Park, E., & Lee, J. (2022). Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. European Journal of Cancer, 174, S72. https://doi.org/10.1016/S0959-8049(22)00992-3

Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. / Hong, D.; Shergill, A.; Bazhenova, L. et al.
In: European Journal of Cancer, Vol. 174, 10.2022, p. S72.

Research output: Contribution to journal › Article › peer-review

Hong, D, Shergill, A, Bazhenova, L, Cho, BC, Heist, R, Moreno, V, Falchook, GS, Nagasaka, M, Cassier, P, Besse, B, Kim, DW, Yoon, S, Le, X, Zhao, T, Atwal, S, Park, E & Lee, J 2022, 'Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial', European Journal of Cancer, vol. 174, pp. S72. https://doi.org/10.1016/S0959-8049(22)00992-3

@article{d3463ca2fdce4db6828ae46e07c38979,

title = "Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial",

author = "D. Hong and A. Shergill and L. Bazhenova and Cho, {B. C.} and R. Heist and V. Moreno and Falchook, {G. S.} and M. Nagasaka and P. Cassier and B. Besse and Kim, {D. W.} and S. Yoon and X. Le and T. Zhao and S. Atwal and E. Park and J. Lee",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)00992-3",

language = "English (US)",

volume = "174",

pages = "S72",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET

T2 - Update from the Phase 1 SHIELD-1 trial

AU - Hong, D.

AU - Shergill, A.

AU - Bazhenova, L.

AU - Cho, B. C.

AU - Heist, R.

AU - Moreno, V.

AU - Falchook, G. S.

AU - Nagasaka, M.

AU - Cassier, P.

AU - Besse, B.

AU - Kim, D. W.

AU - Yoon, S.

AU - Le, X.

AU - Zhao, T.

AU - Atwal, S.

AU - Park, E.

AU - Lee, J.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85140474641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140474641&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)00992-3

DO - 10.1016/S0959-8049(22)00992-3

M3 - Article

AN - SCOPUS:85140474641

SN - 0959-8049

VL - 174

SP - S72

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this